Aung Nini, Bowers Margaret, Brearton Gillian, Charlton Andrew, Craig Joanne, Cullis Jonathan, Dang Ray, Donaldson David, Drake Mary, Hall Rachel, Parkins Elizabeth, Tighe Jane, Bygrave Ceri, Sheehy Oonagh
North Tees and Hartlepool NHS Foundation Trust Stockton-on-Tees Hartlepool UK.
Ulster Hospital Southeastern Health and Social Care Trust Dundonald UK.
EJHaem. 2024 Aug 6;5(5):987-991. doi: 10.1002/jha2.913. eCollection 2024 Oct.
This report describes the characteristics and outcomes of 18 heavily pretreated patients with multiple myeloma (MM) who were subsequently treated with selinexor. This is a case series of 18 patients with MM who were treated with selinexor and dexamethasone (Sd) or selinexor, bortezomib, and dexamethasone (SVd) in 12 hospitals in the UK between 2019 and 2021. Eight patients received Sd and 10 patients received SVd. Patients received a median of five prior treatment lines, including immunomodulatory agents in 94% and proteasome inhibitors in 94%. Ten patients (55%) had triple-class refractory disease. Six of the 12 evaluable patients achieved ≥partial response. The median progression-free survival was 5.6 months, which was higher with SVd (5.7 months) than with Sd (2.1 months). The results support a treatment benefit of selinexor in heavily pretreated patients and support the notion that selinexor may overcome resistance to prior therapies, with no new safety concerns arising.
本报告描述了18例接受过大量预处理的多发性骨髓瘤（MM）患者的特征及治疗结果，这些患者随后接受了塞利尼索治疗。这是一项针对18例MM患者的病例系列研究，2019年至2021年间，英国12家医院对这些患者采用塞利尼索联合地塞米松（Sd）或塞利尼索、硼替佐米联合地塞米松（SVd）进行治疗。8例患者接受Sd治疗，10例患者接受SVd治疗。患者接受过的治疗线数中位数为5条，其中94%的患者接受过免疫调节剂治疗，94%的患者接受过蛋白酶体抑制剂治疗。10例患者（55%）患有三类难治性疾病。12例可评估患者中有6例达到了≥部分缓解。无进展生存期的中位数为5.6个月，SVd组（5.7个月）高于Sd组（2.1个月）。这些结果支持塞利尼索对接受过大量预处理的患者具有治疗益处，并支持塞利尼索可能克服对既往治疗耐药的观点，且未出现新的安全问题。
